Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07181681 · ClinicalTrials.gov registry record · Phase 1

A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor and Solid Tumors, sponsored by BeOne Medicines.

Recruiting
Registry status
Phase 1
Development phase
63
Enrollment target
8
Study locations

NCT07181681: Recruiting Phase 1 study of Advanced Solid Tumor and Solid Tumors, sponsored by BeOne Medicines.

NCT07181681 is a Phase 1 study of Advanced Solid Tumor and Solid Tumors that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 63 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (67% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07181681, a Phase 1 study of Advanced Solid Tumor and Solid Tumors, is actively recruiting participants, sponsored by BeOne Medicines.

RECRUITING
Registry status
Phase 1
Development phase
63 participants
Enrollment target
8
Study locations

Study Summary

This study is a first-in-human (FIH), Phase 1a/1b study of BG-C0902, a fully humanized anti-epidermal growth factor receptor (EGFR) and anti-mesenchymal-epithelial transition (MET) antibody, conjugated via an enzymatically cleavable linker to a topoisomerase 1 (TOPO1) inhibitor payload. The study aims to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C0902 in participants with advanced solid tumors. The study will be conducted in 2 phases: Phase 1a (dose escalation and safety expansion) and Phase 1b (dose expansion).

Conditions Studied

Advanced Solid Tumor Solid Tumors

Interventions

  • DRUG BG-C0902

Study Locations (8)

Texas

  • The University of Texas Md Anderson Cancer Center - Houston
  • Next Oncology - San Antonio

Victoria

  • Monash Health - Clayton
  • The Alfred Hospital - Melbourne

Virginia

  • Next Virginia - Fairfax

New South Wales

  • Blacktown Cancer and Haematology Centre - Blacktown

Fujian

  • The First Affiliated Hospital of Xiamen University - Xiamen

Zhejiang

  • Zhejiang Cancer Hospital - Hangzhou

Trial Details

FieldValue
Enrollment Target 63 participants
Start Date 2025-11-10
Est. Completion 2027-11-01
Phase Phase 1
BeOne Medicines

29 total trials

What NCT07181681 shows while recruiting

NCT07181681 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (67% lower).

The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which BG-C0902 is the first listed.

NCT07181681 lists 8 locations in 6 states (Texas, Victoria, Virginia).

Frequently Asked Questions

What is clinical trial NCT07181681 about?

NCT07181681 is a clinical study titled "A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors". This study is a first-in-human (FIH), Phase 1a/1b study of BG-C0902, a fully humanized anti-epidermal growth factor receptor (EGFR) and anti-mesenchymal-epithelial transition (MET) antibody, conjugated via an enzymatically cleavable linker to a topoisomerase 1 (TOPO1) inhibitor payload. The study ai...

What is the current status of trial NCT07181681?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2025-11-10. Estimated completion is 2027-11-01.

What conditions does trial NCT07181681 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Solid Tumors.

What interventions are being tested in trial NCT07181681?

The interventions under investigation include: BG-C0902 (DRUG).

Who is sponsoring clinical trial NCT07181681?

This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07181681 being conducted?

This trial has 8 study locations across Texas, Virginia, New South Wales, Victoria, Fujian. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07181681's enrollment target sits among peer trials

63 152nd of 189 higher than 38 of 189 other Advanced Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03383575 · 63 participants · Phase 2

    Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

  • NCT04870944 · 63 participants · Phase 1

    CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

  • NCT05031897 · 63 participants · Phase 2

    Two Step Haplo With Radiation Conditioning

  • NCT05312671 · 63 participants · Phase 2

    Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07181681

Source: ClinicalTrials.gov NCT07181681, the US trial registry maintained by the National Library of Medicine. NCT07181681 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.